Digital biomarker‐based individualized prognosis for people at risk of dementia
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: Research investigating treatments and interventions for cognitive decline fail due to difficulties in accurately recognizing behavioral signatures in the presymptomatic stages of the disease. For this validation study, we took our previously constructed digital biomarker-based prognostic models and focused on generalizability and robustness of the models. Method: We validated prognostic models characterizing subjects using digital biomarkers in a longitudinal, multi-site, 40-month prospective study collecting data in memory clinics, general practitioner offices, and home environments. Results: Our models were able to accurately discriminate between healthy subjects and individuals at risk to progress to dementia within 3 years. The model was also able to differentiate between people with or without amyloid neuropathology and classify fast and slow cognitive decliners with a very good diagnostic performance. Conclusion: Digital biomarker prognostic models can be a useful tool to assist large-scale population screening for the early detection of cognitive impairment and patient monitoring over time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Prediction models need appropriate internal, internal-external, and external validation
Steyerberg, E. W., & Harrell, F. E. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.04.005 · Cited by 1,304 · cited 1×
“We validated our results using both internal-external and external validation as proposed by Steyerberg and Harrell (2016).27 For internal-external validation, we used five-fold cross-validation using all applicable subjects fromStudyAanda leave-maximum-one-center-out scheme.”
MethodConnections between sleep and cognition in older adults
Yaffe, K., Falvey, C. M., & Hoang, T. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70172-3 · Cited by 796
Mosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E. M., Holthoff, V., Kalbe, E., Sorbi, S., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045385 · Cited by 726
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Self-citationCollins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.025 · Cited by 439
Machine learning for comprehensive forecasting of Alzheimer’s Disease progression
Fisher, C. K., Smith, A. M., Walsh, J. R., Diseases, C. A. M., Simon, A. J., Edgar, C., Jack, C. R., Holtzman, D., Russell, D., Hill, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49656-2 · Cited by 223
Bhagwat, N., Viviano, J. D., Voineskos, A. N., Chakravarty, M. M., & Initiative, A. D. N. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006376 · Cited by 157
Identifying incipient dementia individuals using machine learning and amyloid imaging
Mathotaarachchi, S., Pascoal, T. A., Shin, M., Benedet, A. L., Kang, M. S., Beaudry, T., Fonov, V. S., Gauthier, S., & Rosa-Neto, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.027 · Cited by 118
Chen, Y., Denny, K. G., Harvey, D., Farias, S. T., Mungas, D., DeCarli, C., & Beckett, L. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.151 · Cited by 98
Tarnanas, I., Tsolaki, M., Nef, T., M. Müri, R., & Mosimann, U. P. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.002 · Cited by 77
Self-citation
Cited by
Machine learning and digital biomarkers can detect early stages of neurodegenerative diseases
Chudzik, A., Śledzianowski, A., & Przybyszewski, A. W. (2024) · Sensors · doi:10.3390/s24051572 · Cited by 122
“This high level of accuracy is significant as it showcases the potential of mobile-based applications in the pre-symptomatic detection of NDs. Altoida’s recognition by regulatory bodies like the FDA and CE further highlights its clinical relevance [82].”
BackgroundAlzheimer's disease digital biomarkers multidimensional landscape and AI model scoping review
Qi, W., Zhu, X., Wang, B., Shi, Y., Dong, C., Shen, S., Li, J., Zhang, K., He, Y., Zhao, M., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01640-z · Cited by 78
“The company received signi fi cant corporate funding to further its research on predicting the progression from mild cognitive impairment to AD 35 .”
Koebel, K., Lacayo, M., Murali, M., Tarnanas, I., & Çöltekin, A. (2022) · Lecture Notes in Computer Science · doi:10.1007/978-3-030-94890-0_2 · Cited by 14
Self-citationReview of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias
Breithaupt, A. G., Tang, A., Paolillo, E. W., Bibars, M., Johnson, E. C. B., Saloner, R., Possin, K. L., Windon, C. C., Hill-Jarrett, T. G., Giorgio, J., et al. (2026) · Seminars in Neurology · doi:10.1055/a-2744-9871 · Cited by 6
Metadata
- Authors
- Buegler, M., Harms, R. L., Balasa, M., Meier, I. B., Exarchos, T., Rai, L., Boyle, R., Tort, A., Kozori, M., Lazarou, E., Rampini, M., Cavaliere, C., Vlamos, P., Tsolaki, M., Babiloni, C., Soricelli, A., Frisoni, G., Sanchez‐Valle, R., Whelan, R., Merlo‐Pich, E., & Tarnanas, I.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2020-01
- Volume
- 12
- Issue
- 1
- Pages
- e12073-e12073
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W3059668454
- Cited by
- 62
- References
- 12
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.